Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO – Get Free Report) have been given a consensus rating of “Buy” by the nine research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $28.00.
CBIO has been the subject of several research analyst reports. Weiss Ratings raised shares of Crescent Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Wednesday. HC Wainwright decreased their price objective on shares of Crescent Biopharma from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Stifel Nicolaus set a $29.00 price target on shares of Crescent Biopharma in a report on Thursday, February 26th. Wall Street Zen upgraded shares of Crescent Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Guggenheim assumed coverage on shares of Crescent Biopharma in a report on Wednesday, January 21st. They issued a “buy” rating and a $35.00 price target on the stock.
Check Out Our Latest Research Report on Crescent Biopharma
Hedge Funds Weigh In On Crescent Biopharma
Crescent Biopharma Price Performance
Shares of Crescent Biopharma stock opened at $19.97 on Wednesday. The firm has a market capitalization of $550.37 million, a P/E ratio of -1.83 and a beta of 1.21. The company has a 50 day moving average price of $17.43 and a 200 day moving average price of $14.00. Crescent Biopharma has a 52 week low of $8.72 and a 52 week high of $27.50.
Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.15. The company had revenue of $1.04 million during the quarter, compared to analysts’ expectations of $0.36 million. As a group, research analysts anticipate that Crescent Biopharma will post -3.22 earnings per share for the current fiscal year.
Crescent Biopharma Company Profile
Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.
The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.
Featured Stories
- Five stocks we like better than Crescent Biopharma
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
